From sourced teaser to closed deal, in one place.
The full-suite platform to buy a business, for small funds, family offices, search funds, and independent sponsors. 29 valuation methods across 43 industries, 11,000+ comparables, 9,000+ M&A precedents, and an automated PDF memorandum on every deal. One workflow. Every stage. Built in PE shape.
Screen, value, and close more deals.
Value Alpha runs on a proprietary data layer built for sub-$100M deals, exactly where the institutional platforms thin out. Put a defensible range and a deal grade on every target.
Where Value Alpha lives in your deal flow.
The bottleneck between sourcing and committee is the analyst-week per target. We move the work earlier: an instant, ungated screen against the live VA Index turns top-of-funnel triage from days into minutes. Senior bandwidth shifts to the deals that actually deserve it.
Five steps. 10 minutes. One defensible range.
Watch the live product walkthrough: upload, 29 valuation methods in parallel, and a defensible range with a at the end.
Value a business in 10 minutes.
Open the platform, drop in the deal, watch the 29 valuation methods run in parallel. End with a defensible VA Range and a. The same workflow your IC will see.
Built for the deal sizes the institutional vendors ignore.
CapitalIQ and PitchBook were built for public markets and large-cap M&A. Brokered platforms are paid on close, not on accuracy. Excel models live in one analyst's head. None of them produce a triangulated, valuation on every sourced target. We do.
| Spreadsheet | PitchBook / CIQ | Brokered platforms | VALUE ALPHA | |
|---|---|---|---|---|
| Audience | One analyst | PE / IB institutions | Sell-side owners | Buy-side deal teams |
| Deal size sweet spot | Any | $100M+ EV | $5M–$100M revenue | $1M–$250M revenue |
| Triangulated valuation output | Single-method DCF | Data only, no output | Black-box AI estimate | 29 valuation methods across 43 industries |
| Published multiples layer | No | Database, not publication | No | Monthly VA Index, immutable |
| Reliability score per output | No | No | No | VARI 0–100, three bands |
| Free top-of-funnel screen | N/A | Subscription only | Gated to mandate | 10 min · email valuation also available |
| Methodology audit trail | Whoever opened the file | N/A | No | Full ledger per output |
| Deal pipeline / deal book | No | No | Their pipeline, not yours | Sourced to closed, VA Range on every card |
| Portfolio tracking after close | No | No | No | Re-valued on the same models |
| Data room | No | No | Per mandate | Built in, with a controlled share link |
| Sector-specific model | No | No | Generic multiple | 43 industries supported, switched on by NAICS |
Twenty-nine valuation methods. Every range VARI-scored.
Every Value Alpha output runs through 29 valuation methods in parallel, with sector-tailored variants on top (rNPV for biotech, SOTP for diversified holdcos, Bottom-Up for marketplace SaaS, and others). Disagreement between engines is surfaced in the VARI score, decomposed into five components, so an IC member knows where the weakness is before they ask.
What the future cash flow is worth today, discounted for risk. A full three-statement build, with the cost of capital and terminal value each stress-tested two independent ways so the result holds up under scrutiny.
What public companies in the same industry are worth right now, scaled to this size. Screened by NAICS, geography, size and growth, normalized for the differences, then converted to an equity value.
What buyers actually paid for similar businesses. Drawn from 9,000+ completed transactions, filtered to the subject profile by sector and size, with control premium and time-decay corrections. Built for deals the public comps cannot price.
The lowest number the business should trade at, based on what it owns. Adjusted book value with hard-asset revaluation, setting the downside anchor for the range when earnings power is in question.
Bear, base, and bull trajectories with explicit, named assumption changes. These set the three anchor points inside the VA Range.
The business run 10,000+ times across good and bad conditions to see where the value actually lands and how likely each outcome is. The resulting probability distribution sets the 80% confidence band.
A forward build of revenue, margins, and cash under an explicit bull case and bear case, so the range reflects how the business does if growth holds and if it stalls.
How long the business can operate on current cash and cash flow before it needs capital, and what that means for value under stress. The same solvency check a lender runs.
Value built from the unit up: customers, contracts, locations, or seats times their economics. The check on whether the headline multiple is actually earned.
Value framed from the market down: total addressable market, the share this business holds, and what that position is worth. The sanity check on growth claims.
The price a PE buyer or searcher can pay and still clear their return hurdle. A target-IRR model with a full debt schedule, cash sweep, and sponsor equity returns.
Segment-level valuation for multi-business holdings and diversified operators. Each unit valued on its own best method, then aggregated into one whole-company range.
Pipeline NPV per program with phase-transition probabilities applied. The standard for pre-revenue life sciences and biotech, where a single multiple is meaningless.
Growth plus profit blended with NRR, CAC payback, and magic-number adjustments. How software buyers actually price recurring revenue.
Banks run on P/TBV, REITs on cap rate, biotech on rNPV and sum-of-the-parts, MedTech on a market and product forecast. The right one switches on for the target's NAICS code. New models are added at no extra cost on Pro.
The reliability score that defends the range at IC.
A 0 to 100 score on every VA Range, decomposed into five components, so methodology disagreement is surfaced before it is challenged.
Every role that has to defend a number.
Four buyer audiences. One platform. One methodology. One sector-multiples publication.
ETA searchers & search funds
Win deals against PE. Price targets faster than the seller can re-price. Cohort-friendly multi-seat economics.
Independent sponsors & PE
Screen 5–10× more targets at the same headcount. VA Ranges in hours, not analyst-weeks.
M&A advisors & boutique banks
White-label option for advisory practices. Compete on rigor against larger firms without adding headcount.
Family offices & QoE firms
Anchor every QoE engagement with a defensible VA Range. Benchmark portfolio marks against the VA Index monthly.
Three tiers. Built for how deal teams actually buy.
Dollar amounts live on the pricing page. The structural overview below shows what each tier is built for.
One Report
Per-report, one-time, instant. For one-off decisions, fairness checks, and pre-LOI snapshots.
Pro
Subscription. Cmd+K command line, unlimited valuations, AI chat, market intel, deal book. For individual searchers, advisors, analysts.
Team
For PE, search funds, advisory teams. Multi-seat (5-seat minimum), shared deal book, audit trail, annual billing, methodology lock, white-label option.
The questions deal teams open with.
What is the Deal Pipeline?+
What is the Email Valuation service?+
What is the VA Index?+
How is Value Alpha different from CapitalIQ or PitchBook?+
How does VARI work?+
Can VA Range outputs survive PE-grade diligence?+
What does multi-seat Team pricing include?+
Price a target the day you source it, not the week before committee.
29 valuation methods across 43 industries, a PDF memorandum on every run, and a deal pipeline that carries the range and its reliability score from sourced to closed.
